

Prior Authorization Request Form for  
certolizumab ( **Cimzia** )



JOHNS HOPKINS  
HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

**FAX Completed Form and  
Applicable Progress Notes to:  
(410) 424-4037**

## USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

**Questions?** Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

**Step 1** Please complete patient and physician information (please print):

Patient Name:	_____	Physician Name:	_____
Address:	_____	Address:	_____
Sponsor ID #	_____	Phone #:	_____
Date of Birth:	_____	Secure Fax #:	_____

**Step 2** Please complete the clinical assessment:

1. Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	<input type="checkbox"/> Yes proceed to question 2	<input type="checkbox"/> No proceed to question 4
2. Has the patient had an inadequate response to Humira?	<input type="checkbox"/> Yes proceed to question 5	<input type="checkbox"/> No proceed to question 3
3. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	<input type="checkbox"/> Yes proceed to question 5	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
4. Does the patient have a contraindication to Humira (adalimumab)?	<input type="checkbox"/> Yes proceed to question 5	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
5. Is the patient 18 years of age or older?	<input type="checkbox"/> Yes proceed to question 6	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
6. Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers, including CIMIZA. Is the prescriber aware of this?	<input type="checkbox"/> Yes proceed to question 7	<input type="checkbox"/> No <b>STOP</b> Coverage not approved

## Prior Authorization Request Form for certolizumab ( **Cimzia** )

<b>7. What is the indication or diagnosis?</b>	<input type="checkbox"/> moderate to severe active <b>rheumatoid arthritis</b> – proceed to question <b>10</b> <input type="checkbox"/> active <b>psoriatic arthritis</b> – proceed to question <b>10</b> <input type="checkbox"/> active <b>ankylosing spondylitis</b> – proceed to question <b>11</b> <input type="checkbox"/> moderately to severely active <b>Crohn’s disease</b> – proceed to question <b>10</b> <input type="checkbox"/> moderate to severe plaque psoriasis - proceed to question <b>8</b> <input type="checkbox"/> active non-radiographic <b>axial spondyloarthritis</b> with objective signs of inflammation - proceed to question <b>9</b> <input type="checkbox"/> other indication or diagnosis – <b>STOP: coverage not approved.</b>	
<b>8. Is the patient a candidate for systemic therapy or phototherapy?</b>	<input type="checkbox"/> Yes proceed to question <b>12</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>9. Does the patient have evidence of elevated CRP and/or MRI evidence of sacroiliitis AND an Ankylosing Spondylitis Disease Score (ASDAS) greater than or equal to 2.1?</b>	<input type="checkbox"/> Yes proceed to question <b>11</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>10. Has the patient had an inadequate response to non-biologic systemic therapy? (For example: methotrexate, aminosalicylates [e.g. sulfasalazine, mesalamine], corticosteroids, immunosuppressants [e.g. azathioprine], etc.)</b>	<input type="checkbox"/> Yes proceed to question <b>12</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>11. Has the patient had an inadequate response to at least two NSAIDS over a period of at least two months?</b>	<input type="checkbox"/> Yes proceed to question <b>12</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>12. Does the patient have evidence of a negative TB test result in the past 12 months (or TB is adequately managed)?</b>	<input type="checkbox"/> Yes proceed to question <b>13</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>13. Will the patient be receiving other targeted immunomodulatory biologics with Cimzia, including but not limited to the following: Actemra, Cosentyx, Enbrel, Humira, Ilumya, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade, Rituxan, Siliq, Simponi, Stelara, Taltz, Tremfya or Xeljanz/Xeljanz XR?</b>	<input type="checkbox"/> Yes <b>STOP</b> Coverage not approved	<input type="checkbox"/> No Sign and date below

**Step 3** I certify the above is true to the best of my knowledge. Please sign and date:

\_\_\_\_\_

Prescriber Signature

\_\_\_\_\_

Date

[3 February 2020]

For Internal Use Only	
<input type="checkbox"/> Approved:	Duration of Approval: ____month(s)
<input type="checkbox"/> Denied:	Authorized By:
<input type="checkbox"/> Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: